Pharmaceutical

ABBV-101 by AbbVie for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

ABBV-101 is under clinical development by AbbVie and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL).

Jul 7, 2023 - 20:00
ABBV-101 is under clinical development by AbbVie and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL).
Read the original article

Tags:

Previous Article

MesoCancerVac by Amphera for Metastatic Pancreatic Cancer: Likelihood of Approval

Next Article

CC-95775 by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Bacterial Conjunctivitis drugs in development, 2023

Nov 30, 2023

STAT+: Bristol Myers will pay $4.1 billion for cancer startup RayzeBio

STAT+: Bristol Myers will pay $4.1 billion for cancer s...

Dec 27, 2023

Living in disadvantaged neighborhoods linked to higher dementia risk, study finds

Living in disadvantaged neighborhoods linked to higher ...

Jul 20, 2023